IAP Guidelines for the Surgical Management of Acute Pancreatitis
Waldemar Uhl(Heidelberg University), Markus W. B uuml chler(Heidelberg University), David C. Whitcomb(University of Pittsburgh), Charles D. Ulrich(University of Cincinnati), Gerry McEntee(Mater Misericordiae University Hospital), Ross Carter(Glasgow Royal Infirmary), John P. Neoptolemos(University of Liverpool), Eugene Di Magno(Mayo Clinic in Arizona), Jens Werner(Heidelberg University), C W Imrie(Glasgow Royal Infirmary), Werner Hartwig(Heidelberg University), Claudio Bassi(University of Verona), Kat Satake(Osaka City University), Christos Dervenis(Agia Olga Hospital), Peter A. Banks(Brigham and Women's Hospital), Colin J. McKay(Glasgow Royal Infirmary), Andrew L. Warshaw(Massachusetts General Hospital), P. G. Lankisch(Klinikum Lüneburg), Paula Ghaneh(University of Liverpool)
Cited by 774
Related Papers
Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial
|The Lancet|2017|1.9k
Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene
|Nature Genetics|1996|1.6k
Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection
|JAMA|2010|1.4k
Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study
|The Lancet Oncology|2019|1.2k
Chronic pancreatitis: Diagnosis, classification, and new genetic developments
|Gastroenterology|2001|1.2k